NASDAQ: EAREargo Inc Stock
$2.60-0.01 (-0.38%)
Updated Dec 7, 2023
EAR Price
$2.60
Fair Value Price
$2.60
Market Cap
$53.98M
52 Week Low
$1.47
52 Week High
$16.80
P/E
0.17x
P/B
1.2x
P/S
1.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$41.11M
Earnings
-$108.17M
Gross Margin
42%
Operating Margin
-262.9%
Profit Margin
-263.1%
Debt to Equity
0.55
Operating Cash Flow
-$75M
Beta
1.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EAR Overview
Eargo, Inc. manufactures hearing aids. It sells its products directly to consumers and through omnichannels. Known as Aria Innovations, Inc. until 2014, Eargo was founded in 2010 and is based in San Jose, CA.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EAR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EAR ($2.60) is undervalued by 0.15% relative to our estimate of its Fair Value price of $2.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EAR ($2.60) is not significantly undervalued (0.15%) relative to our estimate of its Fair Value price of $2.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EAR was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EAR due diligence checks available for Premium users.
Be the first to know about important EAR news, forecast changes, insider trades & much more!
EAR News
Valuation
EAR fair value
Fair Value of EAR stock based on Discounted Cash Flow (DCF)
Price
$2.60
Fair Value
$2.60
Undervalued by
0.15%
EAR ($2.60) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EAR ($2.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EAR was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EAR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.17x
Industry
34.08x
Market
31.17x
EAR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EAR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
EAR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.2x
Industry
3.55x
EAR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EAR's financial health
Profit margin
Revenue
$8.3M
Net Income
-$17.3M
Profit Margin
-209.5%
EAR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EAR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$69.8M
Liabilities
$24.6M
Debt to equity
0.55
EAR's short-term assets ($56.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EAR's short-term assets ($56.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EAR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.7M
Investing
-$19.0k
Financing
$0.0
EAR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EAR vs Medical Device Stocks
Eargo Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.